Greenlight Competitors

Delisted . USA . 
Stock . Greenlight Biosciences Holdings
GRNADelisted Stock  USD 0.30  0.00  0.00%   
Greenlight Biosciences competes with Lexaria Bioscience, ZyVersa Therapeutics, Biodexa Pharmaceticals, Senti Biosciences, and Cadrenal Therapeutics,; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Greenlight Biosciences competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Greenlight Biosciences to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Greenlight Biosciences competition on your existing holdings.
  
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.300.300.30
Details
Intrinsic
Valuation
LowRealHigh
0.230.230.33
Details

Greenlight Biosciences Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Greenlight Biosciences and its competitors represents the degree of relationship between the price movements of corresponding delisted stocks. A correlation of about +1.0 implies that the price of Greenlight and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Greenlight Biosciences does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
ONCR
+ 0.93
ZVSA
ZVSA
+ 0.85
LEXX
ZIVO
+ 0.85
LEXX
BDRX
+ 0.85
NAVB
ZIVO
+ 0.85
ONCR
ZIVO
+ 0.82
ZVSA
  
High negative correlations   
CVKD
- 0.85
NAVB
CVKD
- 0.78
BDRX
CVKD
- 0.78
LEXX
CVKD
- 0.71
SNTI
CVKD
- 0.66
ZVSA
CVKD
- 0.56
ZIVO

Risk-Adjusted Indicators

There is a big difference between Greenlight Stock performing well and Greenlight Biosciences Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Greenlight Biosciences' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
LEXX  3.12 (0.59) 0.00 (0.33) 0.00 
 0.00 
 7.91 
(6.19)
 27.70 
NAVB  6.04 (1.04) 0.00  2.21  0.00 
 0.00 
 12.50 
(12.50)
 40.40 
ZVSA  3.98 (0.81) 0.00  0.50  0.00 
 0.00 
 7.57 
(9.60)
 78.93 
BDRX  6.93 (1.22) 0.00 (0.25) 0.00 
 0.00 
 13.30 
(17.24)
 97.78 
ONCR  8.13 (2.21) 0.00 (3.66) 0.00 
 0.00 
 10.00 
(21.20)
 120.67 
SNTI  3.12 (0.18) 0.00 (2.49) 0.00 
 0.00 
 7.04 
(7.36)
 29.17 
ZIVO  3.01 (0.96) 0.00 (0.27) 0.00 
 0.00 
 5.31 
(6.67)
 36.36 
CVKD  6.06  1.16  0.18  0.70  6.02 
(6.91)
 17.85 
(9.54)
 47.47 
FHTX  3.91 (0.19) 0.02  0.07  4.41 
(4.24)
 8.50 
(6.81)
 34.64 
QNRX  5.95  0.39  0.06  0.40  6.53 
(8.76)
 17.65 
(9.68)
 74.46 
All Fundamental Data

Greenlight Biosciences Competitive Analysis

The better you understand Greenlight Biosciences competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Greenlight Biosciences' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Greenlight Biosciences' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
GRNA LEXX NAVB ZVSA BDRX ONCR SNTI ZIVO CVKD FHTX
 0.00 
 0.30 
Greenlight
 0.48 
 2.08 
Lexaria
 9.45 
 0.1 
Navidea
 3.60 
 1.07 
ZyVersa
 14.00 
 5.62 
Biodexa
 14.71 
 0.04 
Oncorus
 0.93 
 2.16 
Senti
 0.55 
 1.81 
Zivo
 7.35 
 15.19 
Cadrenal
 2.57 
 7.99 
Foghorn
Market Volatility
(90 Days Market Risk)
Very steady
Unstable
Very steady
Abnormally volatile
Very risky
Very steady
Very risky
Very steady
Relatively risky
Slightly risky
Market Performance
(90 Days Performance)
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Good
Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
Dangerous
Average
Dangerous
Average
Very High
Dangerous
High
Dangerous
Below Average
Below Average
Current Valuation
(Equity Enterprise Value)
Over Valued
Under Valued
Over Valued
Under Valued
Under Valued
Over Valued
Under Valued
Over Valued
Over Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Buy
Not Available
Strong Buy
Strong Buy
Not Available
Buy
Not Available
Strong Buy
Strong Buy
Trade Advice
(90 Days Macroaxis Advice)
Not Rated
Cautious Hold
Not Rated
Strong Sell
Strong Sell
Not Rated
Strong Sell
Not Rated
Hold
Sell
Current Ratio
1.16
40.09
0.22
N/A
N/A
6.42
8.09
2.08
N/A
6.84
Net Asset
148.6 M
8.87 M
4.37 M
22.11 M
10.54 M
145.59 M
119.48 M
2.12 M
8.52 M
285.92 M
EBITDA
(153.99 M)
(5.75 M)
(14.05 M)
(107.74 M)
(7.16 M)
(75.42 M)
(61.34 M)
(8.73 M)
(8.34 M)
(104.45 M)
Operating Margin
-14.93
-20.75
N/A
N/A
-79.31
N/A
-180.17
-133.25
N/A
-3.05
Current Valuation
90.5 M
29.88 M
3.5 M
(611.59 K)
(2.67 M)
25.71 M
34.14 M
2.02 M
20.84 M
215.86 M
Price To Book
2.14
4.52
8.16
0.36
0.3
0.13
0.62
17.86
7.38
10.71
Retained Earnings
(420.64 M)
(51.56 M)
(388 M)
(103.22 M)
(144.77 M)
(272.01 M)
(244.34 M)
(115.8 M)
(15.07 M)
(471.56 M)
Current Asset
N/A
N/A
12.58 M
N/A
N/A
N/A
7.4 M
28.93 K
N/A
N/A
Five Year Return
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
One Year Return
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Beta
1.44
1.06
1.5
0.64
1.44
2.85
2.75
0.27
N/A
3.15
Number Of Employees
10
5
11
7
21
64
48
8
4
116
Shares Outstanding
151.68 M
17.45 M
100.08 M
2.34 M
580.84 K
26.09 M
4.59 M
1.82 M
1.66 M
55.59 M
Three Year Return
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Cash Flow From Operations
(136.73 M)
(4.96 M)
(8.99 M)
(8.72 M)
(6.83 M)
(61.69 M)
(52.4 M)
(7.1 M)
(3.53 M)
(118.11 M)
Annual Yield
N/A
N/A
N/A
N/A
N/A
N/A
N/A
0.0424
N/A
N/A
Total Debt
80.48 M
137.37 K
2.43 M
8.66 K
464 K
70.65 M
37.67 M
445.18 K
21.35 K
45.07 M
Return On Equity
-3.67
-0.71
-11.0
-1.52
-0.97
-1.25
-1.11
-39.56
-1.25
-4.7
Z Score
-6.71
N/A
N/A
N/A
N/A
-4.07
N/A
-87.31
N/A
N/A
Return On Asset
-0.82
-0.38
-1.22
-0.25
-0.38
-0.32
-0.33
-1.65
-0.71
-0.2
Number Of Shares Shorted
1.03 M
342.37 K
2.69 M
28.89 K
16 K
447.72 K
57.98 K
35.47 K
66.02 K
983.47 K
Book Value Per Share
0.14
0.64
-0.011
27.33
24.07
1.19
14.64
-0.63
3.09
-0.51
Current Liabilities
N/A
N/A
6.18 M
N/A
N/A
N/A
1.05 M
4.97 M
N/A
N/A
Total Asset
148.6 M
8.87 M
4.37 M
22.11 M
10.54 M
145.59 M
119.48 M
2.12 M
8.52 M
285.92 M
Debt To Equity
2.3
0.007
1.2
N/A
N/A
0.72
0.2
0.28
N/A
2.19
Short Ratio
0.78
2.34
0.52
0.19
0.04
0.74
3.27
6.65
0.8
7.37
Target Price
0.6
10.0
5.0
20.0
156.43
5.0
6.0
36.0
35.67
16.0
Shares Owned By Institutions
26.85
6.0
1.5
4.47
35.25
55.29
23.32
4.44
4.74
72.1
Market Capitalization
45.43 M
36.48 M
8.04 M
2.52 M
3.26 M
3.15 M
9.91 M
2 M
25.2 M
444.19 M
Price To Earning
N/A
N/A
0.53
N/A
N/A
N/A
N/A
-1.95
N/A
N/A
Price To Sales
41.41
88.75
84.14
N/A
39.33
N/A
29.32
2639.17
N/A
17.41
Net Income
(167.06 M)
(5.81 M)
(15.18 M)
(98.3 M)
(7.08 M)
(77.42 M)
(71.06 M)
(8.75 M)
(8.36 M)
(98.43 M)
Earnings Per Share
-1.12
-0.47
-0.39
491.97
-76.17
-5.49
-15.59
-5.33
-6.73
-1.85
Shares Owned By Insiders
42.9
7.0
35.43
0.61
10.16
12.69
21.0
25.23
34.0
18.98
Revenue
6.38 M
464.28 K
65.65 K
N/A
381 K
N/A
2.56 M
N/A
N/A
34.16 M
Working Capital
35.75 M
1.93 M
(6.74 M)
(6.84 M)
1.46 M
27.41 M
58.53 M
(126.04 K)
7.67 M
181.75 M
Ten Year Return
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Cash And Equivalents
44.13 M
7.34 M
328.01 K
N/A
N/A
100.24 M
140.78 M
5.08 M
N/A
373.5 M
Cash Per Share
0.36
1.23
0.01
N/A
N/A
3.86
3.24
0.54
N/A
8.94
Gross Profit
(87.22 M)
183.56 K
(119.3 K)
N/A
(4.41 M)
N/A
(29.78 M)
20 K
N/A
(86.39 M)
Day Typical Price
0.3
2.14
0.1
1.07
5.39
0.0472
2.15
1.82
14.87
7.92
Accumulation Distribution
N/A
0.0921
0.11
0.0459
0.12
0.37
0.0365
0.0688
0.0878
0.0263
Market Facilitation Index
N/A
0.21
0.012
0.05
0.68
0.022
0.08
0.13
1.35
0.21
Daily Balance Of Power
0.0
(0.05)
(0.87)
(0.80)
1.014706
(0.34)
0.25
(0.08)
0.7704
0.9524
Period Momentum Indicator
N/A
(0.01)
(0.01)
(0.04)
0.69
(0.01)
0.02
(0.01)
1.04
0.2
Rate Of Daily Change
1.0
1.0
0.91
0.96
1.14
0.85
1.01
0.99
1.07
1.03
Day Median Price
0.3
2.17
0.1
1.07
5.28
0.049
2.15
1.83
14.71
7.89
Price Action Indicator
N/A
(0.10)
(0.01)
(0.01)
0.69
(0.01)
0.02
(0.02)
1.0
0.21
Coefficient Of Variation
(2,341)
(1,080)
(762.99)
(753.78)
(1,496)
(655.56)
(2,792)
(722.69)
571.56
2537.48
Mean Deviation
3.31
3.12
6.04
3.98
6.93
8.13
3.12
3.01
6.06
3.91
Jensen Alpha
(0.30)
(0.59)
(1.04)
(0.81)
(1.22)
(2.21)
(0.18)
(0.96)
1.16
(0.19)
Total Risk Alpha
(1.54)
(1.18)
(2.50)
(2.45)
(2.79)
(4.46)
(0.93)
(1.42)
0.0556
(0.69)
Sortino Ratio
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
0.1844
0.0162
Downside Variance
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
49.13
20.27
Standard Deviation
7.29
4.51
8.36
8.15
11.91
13.92
4.53
4.62
8.17
5.34
Kurtosis
23.13
7.13
0.7251
16.03
16.67
11.31
6.57
8.23
1.56
5.3
Potential Upside
5.26
7.91
12.5
7.57
13.3
10.0
7.04
5.31
17.85
8.5
Treynor Ratio
1.85
(0.33)
2.21
0.5039
(0.25)
(3.66)
(2.49)
(0.27)
0.699
0.0653
Maximum Drawdown
48.45
27.7
40.4
78.93
97.78
120.67
29.17
36.36
47.47
34.64
Variance
53.18
20.31
69.93
66.43
141.74
193.82
20.51
21.38
66.8
28.49
Market Risk Adjusted Performance
1.86
(0.32)
2.22
0.5139
(0.24)
(3.65)
(2.48)
(0.26)
0.709
0.0753
Risk Adjusted Performance
(0.02)
(0.06)
(0.09)
(0.09)
(0.04)
(0.11)
(0.02)
(0.1)
0.1428
0.0387
Skewness
3.43
2.01
0.2409
0.3811
2.6
0.7357
(1.48)
1.35
0.7309
1.4
Semi Deviation
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
6.02
4.41
Information Ratio
(0.06)
(0.12)
(0.15)
(0.15)
(0.08)
(0.16)
(0.07)
(0.17)
0.1581
0.0136
Value At Risk
(10.81)
(6.19)
(12.50)
(9.60)
(17.24)
(21.20)
(7.36)
(6.67)
(9.54)
(6.81)
Expected Short fall
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
(6.91)
(4.24)
Downside Deviation
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
7.01
4.5
Semi Variance
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
36.25
19.44

Greenlight Biosciences Competition Performance Charts

Five steps to successful analysis of Greenlight Biosciences Competition

Greenlight Biosciences' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Greenlight Biosciences in relation to its competition. Greenlight Biosciences' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Greenlight Biosciences in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Greenlight Biosciences' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Greenlight Biosciences, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Greenlight Biosciences position

In addition to having Greenlight Biosciences in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Real Estate ETFs Thematic Idea Now

Real Estate ETFs
Real Estate ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Real Estate ETFs theme has 65 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Real Estate ETFs Theme or any other thematic opportunities.
View All  Next Launch
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.

Other Consideration for investing in Greenlight Stock

If you are still planning to invest in Greenlight Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Greenlight Biosciences' history and understand the potential risks before investing.
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Fundamental Analysis
View fundamental data based on most recent published financial statements
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY